factually
Index/Topics/Monoclonal Antibody Treatments for Alzheimer's

Monoclonal Antibody Treatments for Alzheimer's

The approval of monoclonal antibody treatments for early symptomatic Alzheimer’s disease, including aducanumab, lecanemab, and donanemab, by U.S. regulators.

Fact-Checks

1 result
Jan 19, 2026

What recent disease‑modifying Alzheimer's treatments have been approved by regulators?

Three monoclonal antibody treatments that target amyloid-beta have been approved by U.S. regulators in recent years: aducanumab (Aduhelm) in 2021, lecanemab (Leqembi) in 2023 with updated maintenance ...